Flagship Pioneering

Refaccionaria Moderna is a leading automotive parts supplier in northern Mexico, with over 70 years in the market and multiple branches strategically located in metropolitan Monterrey and other states.

Tessera Therapeutics is pioneering Gene Writing™, a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source.

Generate Biomedicines is focused on leveraging advanced computational techniques to design and develop new therapeutic proteins, particularly in the field of biomedicine.

Quotient Therapeutics is pioneering somatic genomics to transform genetically-validated targets into breakthrough medicines, unlocking new therapeutic strategies for various diseases.

Lila Sciences is the world’s first scientific superintelligence platform and autonomous lab for life, chemistry, and materials science. We are building the foundation to apply AI to every aspect of the scientific method, enabling scientists to bring forth solutions in human health and sustainability at a pace and scale never experienced before.

Valo Health is redefining drug discovery by combining real-world data, AI, advanced causal inference techniques, and predictive chemistry to create a powerful drug discovery and development engine.

Profound Therapeutics focuses on novel proteins from the human genome. They aim to elucidate their functions.

Sana Biotechnology is focused on engineered cells as medicines, aiming to repair and control genes or replace missing or damaged cells to address the underlying causes of diseases.

Seres Therapeutics is a clinical stage biotechnology company developing new therapies comprised of rationally selected live bacteria consortia to modulate the human microbiome and revolutionize treatment for serious diseases.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Invests in early-stage life sciences companies, often backing founders when they are no more than an idea.

Fellowship for early-career scientists run by repeat deep-tech founders, prioritizing technical founder quality, for those who've never written business plans, offering up to $1M and not taking IP rights. SciFounders is run by repeat deep-tech founders who previously built Mammoth Biosciences and Conception. The fund is designed for scientists who have never written a business plan and focuses on technical founder quality over trendy ideas, operating as a long-term partner rather than a fixed-cohort program with no formal end date.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

5AM Ventures focuses exclusively on the earliest stages of life sciences companies, often investing at or before seed stage and operating an in-house company-creation engine called the 4:59 Initiative. The firm combines hands-on involvement with partners taking short-term operating roles and remaining deeply engaged throughout a company's life, alongside systematic focus on capital efficiency and faster realizations.